01 — At a Glance
The King Of Private Healthcare Got A Crown. Now What?
Apollo Hospitals just wrapped Q3 FY26 (nine months to Dec 31, 2025) with consolidated revenue of ₹6,477 crore, PAT of ₹502 crore, and EPS of ₹34.93. Full-year FY26 (Apr ’25 – Mar ’26) net profit stands at ₹1,816 crore with 24.3% return over the past one year. The company declared a ₹10 interim dividend per share. Bed count across India: 8,050 operational (as of Sep 2025). Pharmacy network: 6,928 stores (up from 6,030 last year). CCI approved the pharmacy demerger. CRISIL upgraded the outlook to “Positive” in January 2026. And yes, the stock trades at the highest P/E in the entire healthcare peer set.
- 52-Week High / Low₹8,100 / ₹6,002
- TTM Revenue₹24,215 Cr
- TTM PAT₹1,816 Cr
- Full-Year EPS (FY26 9M)₹34.93
- Operational Beds (Q3)8,050
- Book Value₹632
- Price to Book12.2x
- Dividend Yield0.25%
- Debt / Equity0.88x
- Cash in Bank (Sep ’25)₹3,222 Cr
Context Setter: Apollo Hospitals is consolidating the private healthcare moat — 51 hospitals, 8,050 beds, ₹6,477 crore quarterly revenue, and plans to add 3,600 beds over the next 3 years. The stock has delivered 24.3% annual returns over the past year, but trades at a 61.2x P/E, making it the priciest name in the sector. Meanwhile, they’re demerging the pharmacy and digital businesses into a separate listed entity. Either this is genius compounding, or the market has already priced in that future. Time will tell.
02 — Introduction
Asia’s Hospital King Wants To Multiply Its Kingdoms
Apollo Hospitals isn’t just a hospital company anymore. It’s a vertically integrated healthcare-to-pharma-to-diagnostics empire that’s literally reshaping Indian healthcare one bed, one store, one diagnostic centre at a time.
Founded in 1983 by Dr. Prathap C Reddy, the company pioneered corporate healthcare in India when “hospital” meant government buildings with overworked staff and zero air conditioning. Forty-plus years later, Apollo runs 51 hospitals across India with world-class infrastructure, JCI accreditation, and an ARPOB (Average Revenue Per Occupied Bed) of ₹60,588 per day — among the highest in the sector. The company is now worth ₹1.11 lakh crore in market cap.
But here’s what’s wild: they’re not stopping. Management announced plans to add ~3,600 beds over 3 years, even while the pharmacy and digital businesses (Apollo HealthCo and Apollo Healthtech) are being demerged into a separate publicly listed entity. CRISIL just upgraded to “Positive” outlook. The stock returned 24% in a year. And the P/E is 61.2x. Yes, you read that right.
So what’s really happening? Is this a company in hypergrowth mode, or has the market priced in a future that doesn’t exist yet? Let’s find out — with data, not hopes.
Regulatory Backdrop (Jan 2026): CRISIL upgraded outlook to “Positive” from “Stable.” CCI approved pharmacy demerger on Sep 23, 2025. Stock exchanges gave observation letters in Dec 2025. NCLT hearing initiated. Demerger expected within 15–18 months.
03 — Business Model: How Does A Hospital Empire Actually Work?
Three Legs, One Table, Infinite Headaches.
Apollo’s business splits into three key verticals, each feeding the other while pretending to be independent:
Leg 1: Healthcare Services (50% of FY26 H1 revenue). This is the core: 51 hospitals, 8,050 operational beds, ₹3,183 crore quarterly revenue in Q3. Inpatient occupancy hovering at ~67%. Average length of stay: 3.14 days (down from 3.34 last year). The payer mix: 45% insurance, 41% self-pay, 14% government/PSU/others. CONGO-T specialties (Cardiac, Oncology, Neurology, Gastroenterology, Orthopedics, Transplant) are the cash engines — 16% YoY revenue growth, transplants up 50% QoQ in Q3. ARPP per patient in Q3: ₹180,917 (up from ₹173,246 in Q2), driven by higher clinical intensity and insurance contract repricing.
Leg 2: Apollo HealthCo (42% of FY26 H1 revenue). The pharmacy and digital ecosystem. Includes 6,928 pharmacy stores, wholesale distribution (soon merging with Keimed, the largest in India at 4% market share), and Apollo 24×7 (digital health platform with 46+ million users). Q3 revenue: ₹2,827 crore (+20% YoY). EBITDA nearly doubled YoY to ₹128 crore, with pharmacy margins at ~3.3% and digital losses narrowing to ₹29 crore cash burn (the lowest in any quarter). Digital was supposed to hit cash EBITDA breakeven in Q4 FY26, but now expected in Q1 FY27 due to insurance revenue recognition mismatch post GST changes.
Leg 3: Apollo Health & Lifestyle (AHLL, ~8% of revenue). Diagnostics, dental, dialysis, cosmetic, IVF clinics. 2,422 diagnostic centres, 254 dental centres, 161 dialysis centres. Q3 revenue: ₹467 crore (+20% YoY), EBITDA ₹48 crore (+39% YoY) at 10.2% margins. Expansion is mostly organic via store additions and new clinics.
The synergy play: hospital drives inpatient admission → patient buys meds from Apollo Pharmacy → diagnostic tests done at Apollo Diagnostic Centres → discharge medications supplied through pharmacy network. Vertical integration = high margins, recurring revenue, customer stickiness.
Hospitals51Operational Units
Pharmacy Stores6,928Active Network
Diagnostic Centres2,422Footprint
💬 Quick thought: Are diagnostics and pharmacies really “sticky enough” to retain customers post-discharge, or is the company relying on OPD footfall to sustain margins?
04 — Financials Overview
Q3 FY26: The Numbers That Matter
Result type: Quarterly Results (9 months to Dec 31, 2025) | Q3 Annualised EPS: ₹139.7 (Q3 EPS ₹34.93 × 4) | Full-year FY26 (TTM) PAT: ₹1,816 Cr | Full-year FY26 EPS: ₹125
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 6,477 | 5,527 | 6,304 | +17.2% | +2.7% |
| Operating Profit (EBITDA) | 965 | 759 | 941 | +27.1% | +2.5% |
| OPM % (EBITDA margin) | 14.9% | 13.7% | 14.9% | +120 bps | — |
| PAT | 502 | 372 | 463 | +35.0% | +8.4% |
| EPS (₹) | 34.93 | 25.89 | 32.10 | +35.0% | +8.8% |
Behind the Blitz: Revenue +17.2% YoY sounds good until you realize Q3 is typically a seasonally weak quarter (per management). Yet momentum from H1 held. EBITDA margin expanded 120 bps YoY, hitting 14.9% — driven by operating leverage in hospitals (23–25% margins), improving HealthCo profitability, and digital losses narrowing. PAT jumped 35% (not 38.7% as headline) after adjusting for one-off tax items and Pune startup drag (~₹15 crore loss in Q3 for the newly opened 250-bed quaternary hospital). Full-year FY26 EPS stands at ₹125 on TTM basis, making current P/E = ₹7,724 / ₹125 = 61.8x. Ouch.
05 — Valuation: The Great Debate
Is 61.2x P/E Genius Or Just Hype?
Join 10,000+ investors who read this every week.
